IPO plans brewing, Innovent Biologics raises $150M and eyes hundreds of millions more
China’s Innovent Biologics has raised $150 million in a Series E crossover round, with Capital Group Private Markets picking up $90 million of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.